Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1

Conditions

Melanoma 105Carcinoma, Renal Cell 38Leukemia, Myeloid, Acute 36Neoplasm Metastasis 31Neoplasms 22Breast Neoplasms 22Lymphoma, Non-Hodgkin 21Kidney Neoplasms 20Leukemia 18Carcinoma, Non-Small-Cell Lung 18Skin Neoplasms 17Neuroblastoma 17Ovarian Neoplasms 16Colorectal Neoplasms 16Recurrence 14Leukemia, Lymphocytic, Chronic, B-Cell 14Lymphoma 13Myelodysplastic Syndromes 10Uveal Melanoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Follicular 9Head and Neck Neoplasms 9Uterine Cervical Neoplasms 8Multiple Myeloma 8Congenital Abnormalities 8Triple Negative Breast Neoplasms 7Stomach Neoplasms 7Lung Neoplasms 7Hodgkin Disease 7Squamous Cell Carcinoma of Head and Neck 6

Interventions

human papillomavirus vaccine, L1 type 16, 18 40Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 32Papillomavirus Vaccines 24Human Papillomavirus Recombinant Vaccine nonavalent 12Vaccines 11Blood Specimen Collection 10Data Collection 9Colposcopy 9Human Papillomavirus DNA Tests 8Specimen Handling 7Radiotherapy, Intensity-Modulated 7Cisplatin 7Surveys and Questionnaires 6Educational Status 6Early Intervention, Educational 6Carboplatin 6Vaginal Smears 5Vaccines, Synthetic 5Methods 5Engerix-B 4fludarabine 3epigallocatechin gallate 3artesunic acid 3artemisinin 3Watchful Waiting 3Polymerase Chain Reaction 3Patient Navigation 3Paclitaxel 3Observation 3Mass Screening 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Papillomavirus Infections × Interleukin-2 × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

NCT03912831 2023-12-26

Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers

Gilead Sciences

Phase 1 Terminated
8 enrolled 13 charts

Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡